250613-50-4

Upstream product

• 102410-65-1 Fmoc-Phg-OH 
• 1053794-40-3 C₂₅H₂₄N₂O₄ 
• 215178-44-2 (2-hydroxy-1-phenylethyl)carbamic acid 9H-fluoren-9-ylmethyl ester 

Downstream Products

• 266683-34-5 N-(9-fluorenylmethoxycarbonyl)-2-phenylglycinal cyanohydrin 
• 886991-13-5 (+)-(1S,3S,4R,5R)-(S_S)-N(1R)-N-[1-((tert-butyldimethylsilyl)oxy)methyl-2-methylpropyl]-4-hydroxy-3-phenyl-1-(4-methylphenylsulfonimidoylmethyl)-2-aza-(N-tert-butoxycarbonyl)-bicyclo[3.3.0]octane 
• 886991-15-7 C₃₂H₅₀N₂O₃SSi 
• 886991-04-4 (2S,3S,4S,5S)-3-Hydroxy-4,5-dimethyl-2-phenyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 738613-78-0 (2S,3S,4S,5S)-3-(3,5-Bis-trifluoromethyl-benzyloxy)-4,5-dimethyl-2-phenyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 309963-21-1 (2-cyano-2-morpholin-4-yl-1-phenyl-ethyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 

Relevant academic research and scientific papers

Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives

HTS screening identified compound 2a (piperazinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the HCV nonstructural protein NS4B. Extensive SAR studies were performed around 2a and the amide function and the C-3/C-6 cis stereochemistry of the piperazinone core were essential for HCV activity. A 10-fold increase in GT-1 potency was observed when the chiral phenylcyclopropyl amide side chain of 2a was replaced with p- fluorophenylisoxazole-carbonyl moiety (67). Replacing the C-6 nonpolar hydrophobic moiety of 67 with a phenyl moiety (95) did not diminish the GT-1 potency. A heterocyclic thiophene moiety (103) and an isoxazole moiety (108) were incorporated as isosteric replacements for the C-6 phenyl moiety (95), resulting in significant improvement in GT-1b and 1a potency. However, the piperazonone class of compounds lacks GT-2 activity and, consequently, were not pursued further into development.

Alzheimer's disease: Identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS)

The application of dynamic ligation screening (DLS), a methodology for fragment-based drug discovery (FBDD), to the aspartic protease β-secretase (BACE-1) is reported. For this purpose, three new fluorescence resonance energy transfer (FRET) substrates we

Asymmetric synthesis of highly substituted azapolycyclic compounds via 2-alkenyl sulfoximines: Potential scaffolds for peptide mimetics

The application of metalated, enantiomerically pure acyclic and cyclic 2-alkenyl sulfoximines for the synthesis of highly substituted aza(poly)cyclic ring systems is described. The method relies on a one-pot combination of a reagent-controlled allyl transfer reaction to α- or β-amino aldehydes, followed by a Michael-type cyclization of the intermediate vinyl sulfoximines generated in the first step. The sulfur-free target compounds are preferentially obtained by samarium iodide treatment of the sulfonimidoyl substituted heterocycles. In addition to this methodological work, initial results on the biological activity of selected examples are reported. Furthermore, a concept for the transformation of peptidic lead structures into non-peptide mimetics is described, and the relevance of the new approach to highly substituted azaheterocycles in this context is discussed.

Synthesis of highly epimerizable N-protected α-amino aldehydes of high enantiomeric excess

The Dess-Martin periodinane was found to be a superior oxidant for the efficient, epimerization-free synthesis of optically active N-protected α- amino aldehydes from the corresponding N-protected β-amino alcohols. Highly racemization-prone products, including N-Fmoc phenylglycinal and N- trifluoroacetyl α-amino aldehydes, were prepared in ≥95% yield with ≤ 1% epimerization. (C) 2000 Elsevier Science Ltd.